Innovation1 Biotech Past Earnings Performance
Past criteria checks 0/6
Innovation1 Biotech's earnings have been declining at an average annual rate of -73.8%, while the Pharmaceuticals industry saw earnings growing at 1% annually. Revenues have been declining at an average rate of 69% per year.
Key information
-73.8%
Earnings growth rate
14.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | -69.0% |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 31 Aug 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Innovation1 Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Aug 23 | 0 | -14 | 1 | 0 |
| 31 May 23 | 0 | -47 | 2 | 0 |
| 28 Feb 23 | 0 | -48 | 2 | 0 |
| 30 Nov 22 | 0 | -42 | 3 | 0 |
| 31 Aug 22 | 0 | -42 | 3 | 0 |
| 31 May 22 | 0 | -4 | 2 | 0 |
| 28 Feb 22 | 0 | -2 | 1 | 0 |
| 30 Nov 21 | 0 | 1 | 1 | 0 |
| 31 Aug 21 | 0 | 1 | 0 | 0 |
| 31 May 21 | 0 | 0 | 0 | 0 |
| 28 Feb 21 | 0 | 0 | 0 | 0 |
| 30 Nov 20 | 0 | -3 | 0 | 0 |
| 31 Aug 20 | 0 | -3 | 0 | 0 |
| 31 May 20 | 0 | -2 | 0 | 0 |
| 29 Feb 20 | 0 | -2 | 0 | 0 |
| 30 Nov 19 | 0 | 0 | 1 | 0 |
| 31 Aug 19 | 0 | 0 | 1 | 0 |
| 31 May 19 | 0 | -1 | 1 | 0 |
| 28 Feb 19 | 0 | -1 | 1 | 0 |
| 30 Nov 18 | 0 | -1 | 1 | 0 |
| 31 Aug 18 | 0 | -1 | 0 | 0 |
Quality Earnings: IVBT is currently unprofitable.
Growing Profit Margin: IVBT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IVBT is unprofitable, and losses have increased over the past 5 years at a rate of 73.8% per year.
Accelerating Growth: Unable to compare IVBT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IVBT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-13.2%).
Return on Equity
High ROE: IVBT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.